Subsense
Private Company
Funding information not available
Overview
Subsense is pioneering a novel, non-invasive brain-computer interface platform that uses functional nanoparticles as neural antennas and a wearable device for external control. Founded in 2019 and based in San Francisco, the company is targeting major neurological disorders as its initial medical application, with a longer-term vision for cognitive enhancement and human-AI integration. It has raised significant seed funding, opened a lab in Palo Alto, and initiated early regulatory engagement with the FDA, positioning itself as a disruptive player in the competitive neurotech landscape.
Technology Platform
Non-surgical bidirectional brain-computer interface (BCI) platform combining intranasally administered functional nanoparticles (plasmonic for reading, magnetoelectric for stimulation) with a wearable wireless headset for external control and closed-loop operation.
Opportunities
Risk Factors
Competitive Landscape
Subsense competes in the rapidly evolving brain-computer interface space. Its primary differentiator is its non-surgical, nanoparticle-based approach. It faces competition from invasive BCI companies (e.g., Neuralink, Synchron) aiming for high signal fidelity and from non-invasive companies using EEG, fMRI, or focused ultrasound. Its success depends on proving its platform offers a superior balance of efficacy, safety, and scalability compared to these alternatives.